$6.9M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.
HEICO Posts Upbeat Sales, Joins Marathon Digital, Riot Platforms And Other Big Stocks Moving Higher In Tuesday’s Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow Jones futures gaining around 20 points on Tuesday.
Shares of HEICO Corporation (NYSE: HEI) rose in pre-market trading as the company posted better-than-expected sales results for its fourth quarter on Monday.
Fear & Greed Index Moves To ‘Extreme Greed’ Zone; S&P 500 Settles Higher
The CNN Money Fear and Greed index showed some easing in overall market sentiment, but the index moved to the "Extreme Greed" zone on Monday.
The S&P 500 closed higher on Monday after recording gains for the seventh straight week.
Undervalued Cannabis Stock? This Company Could Reach A C$1B Valuation On The Back Of Pre-Roll Sales
With a nearly 50% share in infused pre-rolls, which constitute 70% of its sales, Decibel Cannabis Co. Inc. (TSXV: DB) (OTC: DBCCF) is well-positioned in the market.
Switching From Tomatoes To Cost-Efficient Cannabis Boosts Company’s Stock By 35%
Zuanic & Associates has initiated coverage on Village Farms International (NASDAQ: VFF), assigning an "Overweight" rating.
Why Hut 8 Stock Surged Today
Hut 8 Corp. (NASDAQ: HUT) traded higher on Monday after the company announced it was selected by Celsius debtors to build out a site in Cedarvale, Texas.
Nikola Founder Trevor Milton Sentenced To 4 Years In Prison For Fraud
Nikola Corp (NASDAQ: NKLA) founder Trevor Milton is set to serve time in prison on federal charges after a jury found him guilty of
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday.
The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07. The S&P 500 also rose, gaining, 0.54% to 4,744.58.
Vera Therapeutics’ Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).